Hybrid Dialectical Behavior Therapy for Veterans to Further Reduce Emotion Regulation Problems and Trauma Symptoms (REFRESH)
11. juni 2026 oppdatert av: Arkin
REfreshment of Dialectical Behaviour Therapy for Veterans to Further Reduce Symptoms and Prevent Relapse of Post-traumatic Stress Disorder and Emotion Regulation Symptoms by Guided Self-Help
Around 10% of post-active veterans experience post-traumatic stress disorder (PTSD) many years post-mission.
PTSD in veterans is frequently associated with challenges in emotion regulation, aggression, suicidality, and financial and psychosocial stress.
In 2018, a 12-week clinical treatment programme, the Veterans Intensive Treatment Unit (VIBU), was developed for veterans experiencing these psychiatric symptoms, for whom conventional treatments had proven ineffective.
The VIBU provides patients with trauma-focused and dialectical behaviour therapy (DBT).
A recent study revealed that the VIBU was effective in reducing psychiatric symptoms.
However, a recurrence of symptoms was observed in patients a few months after discharge.
Consequently, an aftercare programme consisting of hybrid DBT is offered to consolidate and repeat the DBT skills and apply them in daily life.
Studieoversikt
Status
Rekruttering
Intervensjon / Behandling
Studietype
Intervensjonell
Registrering (Antatt)
24
Fase
- Ikke aktuelt
Kontakter og plasseringer
Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.
Studiesteder
-
-
North Holland
-
Amstelveen, North Holland, Nederland, 1186 AM
- Rekruttering
- Sinai Center
-
Ta kontakt med:
- Kathleen Thomaes, Senior researcher
- Telefonnummer: 020 545 7200
- E-post: refreshonderzoek@sinaicentrum.nl
-
Ta kontakt med:
- Mariejean Albers, MSc
- E-post: mariejean.albers@sinaicentrum.nl
-
Hovedetterforsker:
- Kathleen Thomaes, Senior researcher
-
-
Deltakelseskriterier
Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
- Voksen
- Eldre voksen
Tar imot friske frivillige
Nei
Beskrivelse
Inclusion Criteria:
- Adult veteran (18 years or older), treated at Sinai Center, with knowledge of DBT
- Primairy diagnosis of PTSD, determined with CAPS-5, resulting from war-related traumas
- Stable for four weeks on their medication (type and doses)
- Able to to do online homework assignments and communicate with their therapist via an eHealth platform
- Dutch speaking
Exclusion Criteria:
- Chronic psychosis (psychotic features as comorbidity from PTSD is allowed) or bipolar disorder type 1
- IQ below 80 or cognitive disorders
- Severe self-harming behaviour, such as auto-mutilation or suicidal ideations as main problem
- Following day treatments or other intensive treatment for residual symptoms
Studieplan
Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Enkeltgruppeoppdrag
- Masking: Ingen (Open Label)
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Eksperimentell: Hybrid DBT
All participants will follow the same hybrid DBT program (i.e., group sessions, individual sessions and online homework assignments).
Randomization will determine the length of the waiting period between baseline and start of the intervention (i.e., hybrid DBT).
|
Hybrid DBT will be provided to veterans who have followed a 3-month inpatient DBT treatment.
The hybrid DBT will include face-to-face skill groups, online individual sessions and online homework assignements.
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
PTSD Checklist for the DSM-5 (PCL-5)
Tidsramme: From the baseline to the end of the follow-up period (between 12-17 months)
|
One of the two main outcomes of this study is PTSD symptom score.
The self-report questionnaire contains 20 questions with answer options ranging from '0 = Not at all' to '4 = Extremely', resulting in a score between 0-80.
A higher score indicates more likelyhood of having PTSD.
|
From the baseline to the end of the follow-up period (between 12-17 months)
|
|
Difficulties in Emotion Regulation Scale Short Form (DERS-SF)
Tidsramme: From the baseline to the end of the follow-up period (between 12-17 months)
|
One of the two main outcomes of this study is emotion dysregulation severity.
The self-report questionnaire contains 18 questions with answer options from '1 = Almost never' to '5 = Almost always', resulting in a score between 18-90.
A higher score indicates more difficulties with regulation emotions.
|
From the baseline to the end of the follow-up period (between 12-17 months)
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
REFRESH - monitoring
Tidsramme: From enrollment to (favourably) the end of the follow-up period (between 12-17 months)
|
Weekly short questionnaire (i.e., 10 questions) specifically tailored to this population to monitore PTSD, emotion regulation, substance use and DBT skills.
Answer options range from '1 = Totally disagree' to '10 = Totally agree', resulting in a score between 10-100.
A higher score means a worse outcome.
|
From enrollment to (favourably) the end of the follow-up period (between 12-17 months)
|
Andre resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Outcome Questionnaire (OQ-30.2)
Tidsramme: From the baseline to the end of the follow-up period (between 12-17 months)
|
This self-report questionnaire gives an indication of overall psychiatric symptoms and entails 30 items.
Answers options go from '0 = almost never' to '4 = almost alywas'.
The score ranges between 0-120, with a higher score indicating a worse outcome.
|
From the baseline to the end of the follow-up period (between 12-17 months)
|
|
Alcohol Use Disorders Identification Test (AUDIT)
Tidsramme: From the baseline to the end of the follow-up period (between 12-17 months)
|
This self-report questionnaire contains 10 items with answer options from '0 = never' to '4 = high usage', resulting in a score between 0-40.
A higher score indicates having alcohol problems.
|
From the baseline to the end of the follow-up period (between 12-17 months)
|
|
Drug Use Disorders Identification Test (DUDIT)
Tidsramme: From the baseline to the end of the follow-up period (between 12-17 months)
|
This self-report questionnaire contains 11 items with answer options from '0 = never' to '4 = high usage', resulting in a score between 0-40.
A higher score indicates having drug problems.
|
From the baseline to the end of the follow-up period (between 12-17 months)
|
|
Individual Recovery Outcome Counter (i-ROC)
Tidsramme: From the baseline to the end of the follow-up period (between 12-17 months)
|
This questionnaires measures wellbeing outcomes.
This self-report questionnaire of 12 items uses answer options from '1 = Never' to '6 = Always', resulting in a score ranging between 12-72.
A higher score indicates a better outcome.
|
From the baseline to the end of the follow-up period (between 12-17 months)
|
|
General Self-Efficacy Scale (GSES)
Tidsramme: From the baseline to the end of the follow-up period (between 12-17 months)
|
This questionnaire measures self-efficacy.
This self-report questionnaire of 10 items, with answer options from '1 = Not at all true' to '4 = Exactly true', with scores ranging from 10-40.
A higher score indicates more self-efficacy.
|
From the baseline to the end of the follow-up period (between 12-17 months)
|
|
Dialectical behavioral therapy skills (DBT-skills)
Tidsramme: From the baseline to the end of the follow-up period (between 12-17 months)
|
This questionnaire asks participants about their use of DBT skills.
This self-report questionnaire of 17 items has answer options from '1 = never' to '5 = often', giving a score rangen between 17-85.
A higher score indicates a positive outcome.
|
From the baseline to the end of the follow-up period (between 12-17 months)
|
|
Level of Personality Functioning Scale (LPFS 2.0)
Tidsramme: From the baseline to the end of the follow-up period (between 12-17 months)
|
This questionnaire measures the level of personality functioning.
This self-report questionnaire contains 12 items, with answers ranging from '1 = not often true' to '4 = often true', resulting in a score between 12-48.
A higher score indicates a worse outcome.
|
From the baseline to the end of the follow-up period (between 12-17 months)
|
|
Inventarisatielijst Sociale Betrokkenheid (ISB)
Tidsramme: From the baseline to the end of the follow-up period (between 12-17 months)
|
This questionnaire is about social wellbeing.
This self-report questions contains 11 items, with results from '1 = almost never' to '4 = almost always', resulting in a score between 11-44.
A higher score indicates a positive outcome.
|
From the baseline to the end of the follow-up period (between 12-17 months)
|
|
Aggression questionnaire (AGQ)
Tidsramme: From the baseline to the end of the follow-up period (between 12-17 months)
|
This questionnaire measures different forms of aggression.
This self-report questionnaire contains 29 items, with answer from '1 = Extremely uncharacteristic' to '5 = Extremely characteristic', resulting in a score between 29-145.
A higher score indicates a worse outcome.
|
From the baseline to the end of the follow-up period (between 12-17 months)
|
|
Suicidal Ideation Attributes Scale (SIDAS)
Tidsramme: From the baseline to the end of the follow-up period (between 12-17 months)
|
This questionnaire measures suicidal ideation.
This self-report questionnaire contains 5 items, with answer from '0 = Not at all' to '10 = Completely', resulting in a score between 0-50.
A higher score indicates a higher level of suicidal ideation.
|
From the baseline to the end of the follow-up period (between 12-17 months)
|
|
Non-Suicidal Self-Injury Assement Tool screener (NSSI-AT screener)
Tidsramme: From the baseline to the end of the follow-up period (between 12-17 months)
|
This questionnaire measures self-injurious behavior.
This self-report questionnaire contains 7 items asking about the frequency and severity of self-injurious behaviour.
There is no scoring.
|
From the baseline to the end of the follow-up period (between 12-17 months)
|
|
Childhood Trauma Questionnaire (CTQ)
Tidsramme: At baseline
|
This questionnaire assess childhood maltreatment.
This self-report questionnaire contains 28 items, with answers from '1 = Never true' to '5 = Very often true', resulting in a score between 28-140.
A higher score indicate a worse outcome.
|
At baseline
|
Samarbeidspartnere og etterforskere
Det er her du vil finne personer og organisasjoner som er involvert i denne studien.
Sponsor
Studierekorddatoer
Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.
Studer hoveddatoer
Studiestart (Faktiske)
1. juni 2026
Primær fullføring (Antatt)
1. september 2028
Studiet fullført (Antatt)
1. oktober 2028
Datoer for studieregistrering
Først innsendt
23. februar 2026
Først innsendt som oppfylte QC-kriteriene
11. juni 2026
Først lagt ut (Faktiske)
17. juni 2026
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
17. juni 2026
Siste oppdatering sendt inn som oppfylte QC-kriteriene
11. juni 2026
Sist bekreftet
1. juni 2026
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- REFRESH
- NL-010470 (Registeridentifikator: METC Amsterdam)
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
NEI
IPD-planbeskrivelse
Very sensitive personal information.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Nei
Studerer et amerikansk FDA-regulert enhetsprodukt
Nei
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .